Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
BACKGROUND: Drug eluting beads (DEB) are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. This technique is associated with reduced systemic side effects relative to systemic chemotherapy and an increase in the dose of antineo...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4118844?pdf=render |
id |
doaj-ddd6a71c3a00488fb94b6ec6b33ce5b7 |
---|---|
record_format |
Article |
spelling |
doaj-ddd6a71c3a00488fb94b6ec6b33ce5b72020-11-24T21:42:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10268610.1371/journal.pone.0102686Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.Shilong HanXiaoping ZhangLiling ZouChenhui LuJun ZhangJue LiMaoquan LiBACKGROUND: Drug eluting beads (DEB) are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. This technique is associated with reduced systemic side effects relative to systemic chemotherapy and an increase in the dose of antineoplastic agent delivered to the lesion. The meta-analysis was undertaken to assess the effectiveness of DEB-transcatheter arterial chemoembolization (TACE) in the management of hepatocellular cancer. METHODS: We searched the Web of Science, PubMed, EBSCO, EMBASE, the Wiley Library and Google Scholar for studies on DEB-TACE in the management of hepatocellular cancer from 1979 to April 2013. The risk of bias was assessed using RevMan 5 · 1. Random and fixed-effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. Disease control, complications and severe complications were recorded. RESULTS: Five studies met the selection criteria, three RCTs and two case-control studies, published from 2010 to 2012, included 217 patients in the DEB-TACE group and 237 in the conventional-TACE group. There was no significance over disease control (OR 2.27, 95% CI 0.78-6.63) with moderate between-study heterogeneity (χ(2) = 6.83, degrees of freedom [df] = 3; p<0.08; I(2) = 56%). Complications in both groups were assessed and no significant difference was observed (χ(2) = 6.34, degrees of freedom [df] = 4; p<0.18; I(2)= 37%). Severe complications were also assessed and no significant difference was observed (χ(2) = 6.47, degrees of freedom [df] = 4; p<0.17; I(2)= 38%). No publication bias relating to the above outcomes was detected by funnel plot. DEB-TACE benefited disease control without an increase in complications and severe complications.http://europepmc.org/articles/PMC4118844?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shilong Han Xiaoping Zhang Liling Zou Chenhui Lu Jun Zhang Jue Li Maoquan Li |
spellingShingle |
Shilong Han Xiaoping Zhang Liling Zou Chenhui Lu Jun Zhang Jue Li Maoquan Li Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS ONE |
author_facet |
Shilong Han Xiaoping Zhang Liling Zou Chenhui Lu Jun Zhang Jue Li Maoquan Li |
author_sort |
Shilong Han |
title |
Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. |
title_short |
Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. |
title_full |
Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. |
title_fullStr |
Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. |
title_full_unstemmed |
Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. |
title_sort |
does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? a meta-analysis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
BACKGROUND: Drug eluting beads (DEB) are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. This technique is associated with reduced systemic side effects relative to systemic chemotherapy and an increase in the dose of antineoplastic agent delivered to the lesion. The meta-analysis was undertaken to assess the effectiveness of DEB-transcatheter arterial chemoembolization (TACE) in the management of hepatocellular cancer. METHODS: We searched the Web of Science, PubMed, EBSCO, EMBASE, the Wiley Library and Google Scholar for studies on DEB-TACE in the management of hepatocellular cancer from 1979 to April 2013. The risk of bias was assessed using RevMan 5 · 1. Random and fixed-effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. Disease control, complications and severe complications were recorded. RESULTS: Five studies met the selection criteria, three RCTs and two case-control studies, published from 2010 to 2012, included 217 patients in the DEB-TACE group and 237 in the conventional-TACE group. There was no significance over disease control (OR 2.27, 95% CI 0.78-6.63) with moderate between-study heterogeneity (χ(2) = 6.83, degrees of freedom [df] = 3; p<0.08; I(2) = 56%). Complications in both groups were assessed and no significant difference was observed (χ(2) = 6.34, degrees of freedom [df] = 4; p<0.18; I(2)= 37%). Severe complications were also assessed and no significant difference was observed (χ(2) = 6.47, degrees of freedom [df] = 4; p<0.17; I(2)= 38%). No publication bias relating to the above outcomes was detected by funnel plot. DEB-TACE benefited disease control without an increase in complications and severe complications. |
url |
http://europepmc.org/articles/PMC4118844?pdf=render |
work_keys_str_mv |
AT shilonghan doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis AT xiaopingzhang doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis AT lilingzou doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis AT chenhuilu doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis AT junzhang doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis AT jueli doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis AT maoquanli doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis |
_version_ |
1725916729377292288 |